论文部分内容阅读
免疫抑制患者患肺孢子虫性肺炎后,如不治疗常常死亡。几年来,戊烷脒(Pentamidine)已用于治疗这种感染。虽有报道说其治愈率达9～77％,但药物的不良反应率(主要是肾中毒)达50％。新近,Hughes等曾用增效磺胺合剂(复方新诺明TMP+SMZ)治疗儿童白血病患者的肺孢子虫性肺炎,治愈率达80％。本文主要报道本药对成年人肺孢子虫性肺炎的疗效。对象为8例肺孢子虫性肺炎患者,男5,女3,年龄19～72岁。6例原有肿瘤,1例曾接受尸体的肾移植,2例曾接受骨髓移植(再生障碍性贫血和急性杆状细胞性白血病各1例)。治疗前1～10天(平均3天)有肺孢子虫性肺炎的症状和体征,胸部X线照
Immunocompromised patients suffering from pneumocystis pneumonia, often died if not treated. Pentamidine has been used for several years to treat this infection. Although it is reported that the cure rate of 9 to 77%, but adverse drug reactions (mainly nephrotoxicosis) up to 50%. Recently, Hughes et al have been treated with synergistic sulfonamide (cotrimoxazole TMP + SMZ) in patients with childhood leukemia pneumocystis pneumonia, the cure rate of 80%. This article mainly reports the efficacy of the drug on adult Pneumocystis carinii pneumonia. Subjects were 8 cases of pneumococcal pneumonia, male 5, female 3, aged 19 to 72 years. Six of the original tumors, one who had undergone renal transplantation, and two who had undergone bone marrow transplantation (one for each of aplastic anemia and acute myelocytic leukemia). 1 to 10 days before treatment (average 3 days) have symptoms and signs of pneumococcal pneumonia, chest X-ray